What do we know about canine osteosarcoma treatment? – review

Szewczyk, M.; Lechowski, R.; Zabielska, K.

doi:10.1007/s11259-014-9623-0

Cited by 96 publications

(133 citation statements)

References 48 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…Essa prática baseia-se na administração de agentes antineoplásicos, os quais exercem efeitos citotóxicos nas células tumorais. Um dos benefícios da quimioterapia é o prolongamento da vida do paciente, principalmente quando associada à outras formas de tratamento, como a cirurgia de amputação do membro afetado (SZEWCZYK et al 2015).…”

Section: Quimioterapiaunclassified

“…É uma das drogas mais utilizadas nos protocolos quimioterápicos e associações de medicamentos (JAFFE et al 2013). Nos cães, os primeiros estudos envolvendo essa droga iniciaram-se em 1995, com bons resultados no retardamento da ocorrência de metástases em osteossarcoma apendicular (SZEWCZYK et al 2015).…”

Section: Doxorrubicinaunclassified

“…As drogas mais utilizadas para o tratamento dos animais incluem a carboplatina, cisplatina e doxorrubicina (SZEWCZYK et al 2015).…”

unclassified

“…Nos animais, a associação entre os tratamentos também promoveu melhoras e reduziu a ocorrência de metástases, mas vários são os efeitos tóxicos dos medicamentos utilizados (SZEWCZYK et al 2015).…”

unclassified

“…Embora a mortalidade dos pacientes tenha diminuído, não houve melhora significativa nas taxas de cura nos últimos 30 anos, o que torna necessário o desenvolvimento de pesquisas sobre novas drogas e tratamentos alternativos, para melhorar os resultados, a expectativa de vida dos pacientes e diminuir os efeitos adversos (HATTINGER et al 2015;SZEWCZYK et al 2015).…”

unclassified

See 4 more Smart Citations

Agentes Antineoplásicos Para O Tratamento Do Osteossarcoma

Gabriel¹,

Nepomuceno²,

Pimenta³

et al. 2017

Enci Bio

View full text Add to dashboard Cite

RESUMOO osteossarcoma é o tumor ósseo de maior ocorrência, sendo seu estudo importante nas espécies humana e canina. As crianças e jovens são mais frequentemente acometidas, por estarem em uma idade quando ocorre maior crescimento ósseo, sendo que o contrário ocorre nos animais, que são acometidos geralmente com idade avançada entre seis a 10 anos. A etiologia do tumor é desconhecida e as taxas de mortalidade são altas, variando de 40 a 50% para os humanos e chegando até 80% nos animais. O tratamento é baseado na remoção cirúrgica do tumor e quimioterapia, associação esta que permitiu melhora nos resultados dos tratamentos, mas cursa com intensa toxicidade e inúmeros efeitos adversos para os pacientes. Sem melhora significativa nas taxas de cura nos últimos 30 anos, a busca de tratamentos alternativos para o osteossarcoma é necessária para aumentar a expectativa de vida dos pacientes e diminuir a ocorrência de efeitos adversos. PALAVRAS-CHAVE: oncologia comparativa, quimioterapia, toxicidade. ANTINEOPLASTIC AGENTS FOR THE TREATMENT OF OSTEOSARCOMA ABSTRACTOsteosarcoma is the most frequent bone tumor, being important in both medicine and veterinary medicine. Children and youngsters are more frequently affected because they are at an age where there is greater bone growth, whereas the opposite occurs in animals, which are usually affected at an advanced age between 6 and 10 years. The etiology of the tumor is unknown and mortality rates are high, ranging from 40 to 50% for humans and up to 80% in animals. The treatment is based on the surgical removal of the tumor and chemotherapy, an association that allowed improvement in the results of the treatments, but presents with intense toxicity and numerous adverse effects for the patients. Without significant improvement in cure rates over the past 30 years, the search for alternative

show abstract

Section: Quimioterapiaunclassified

Section: Doxorrubicinaunclassified

“…As drogas mais utilizadas para o tratamento dos animais incluem a carboplatina, cisplatina e doxorrubicina (SZEWCZYK et al 2015).…”

unclassified

See 3 more Smart Citations

Agentes Antineoplásicos Para O Tratamento Do Osteossarcoma

Gabriel¹,

Nepomuceno²,

Pimenta³

et al. 2017

Enci Bio

View full text Add to dashboard Cite

show abstract

Myricetin treatment induces apoptosis in canine osteosarcoma cells by inducing DNA fragmentation, disrupting redox homeostasis, and mediating loss of mitochondrial membrane potential

Park

Bazer

Lim

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Canine osteosarcoma is an aggressive primary bone tumor that shows metastasis to distal regions and is associated with a high mortality rate. However, the pathophysiological mechanisms of canine osteosarcoma are not well characterized. In addition, development of prognostic factors and novel therapeutic agents is necessary to efficiently treat osteosarcoma. Therefore, we studied the effects of myricetin, an antioxidant found in berries, nuts, teas, wine, and vegetables, on apoptosis and signal transduction in the canine osteosarcoma cell lines, D-17 and DSN. Results of the present study demonstrated that treatment with myricetin decreased cell proliferation and DNA replication, while it increased apoptotic DNA fragmentation in D-17 and DSN cells. In addition, it increased generation of ROS, lipid peroxidation, and depolarization of MMP in both D-17 and DSN cells. Myricetin treatment activated phosphorylation of AKT, p70S6K, ERK1/2, JNK, and p90RSK in canine osteosarcoma cells. Moreover, inhibition of PI3K and MAPK using LY294002, U0126, or SP600125, in addition to myricetin treatment, effectively suppressed cell proliferation compared to treatment with myricetin or each inhibitor alone. Therefore, we concluded that myricetin may be a potentially effective and less toxic therapeutic agent to prevent and control progression of canine osteosarcoma.

show abstract

Effects of luteolin on canine osteosarcoma: Suppression of cell proliferation and synergy with cisplatin

Ryu

Lim

Song

2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Canine osteosarcoma is characterized by aggressiveness, easy metastasis to the lungs, and high mortality after standard therapy. Luteolin is a flavonoid found in vegetables and fruits and has diverse functions. Elucidation of the biological mechanisms of luteolin on canine osteosarcoma will enhance the efficacy of chemotherapeutic agents in canine tumors. In this study, we examined the effects of luteolin in the canine osteosarcoma cell lines, D17 and DSN. The results of this study show that luteolin inhibited canine osteosarcoma cell proliferation and induced apoptosis by altering cell‐cycle proportion, producing reactive oxygen species, increasing the loss of mitochondrial membrane potential, and reducing cytosolic Ca2+ concentration. In addition, luteolin activated ERK1/2 and inactivated phosphoinositide 3‐kinase/AKT signaling in canine osteosarcoma cells. Moreover, luteolin showed synergistic effects with cisplatin to reduce cell proliferation. In summary, luteolin induced cell death by initiating mitochondrial dysfunction and regulating intracellular signal transduction in canine osteosarcoma cells.

show abstract

What do we know about canine osteosarcoma treatment? – review

Cited by 96 publications

References 48 publications

Agentes Antineoplásicos Para O Tratamento Do Osteossarcoma

Agentes Antineoplásicos Para O Tratamento Do Osteossarcoma

Myricetin treatment induces apoptosis in canine osteosarcoma cells by inducing DNA fragmentation, disrupting redox homeostasis, and mediating loss of mitochondrial membrane potential

Effects of luteolin on canine osteosarcoma: Suppression of cell proliferation and synergy with cisplatin

Contact Info

Product

Resources

About